PIB binding in aged primate brain: Enrichment of high-affinity sites in humans with Alzheimer's disease

Neurobiology of Aging

Volumn 32, Issue 2, 2011, Pages 223-234

  Rosen, Rebecca F ^a   Walker, Lary C ^a,b   LeVine, Harry ^c  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Amyloid; A ; Alzheimer's disease; Benzothiazole; Cerebral amyloid angiopathy; Imaging; Nonhuman primates; Pittsburgh Compound B; Senile plaques

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

ADULT; AGED; AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOPHYSICS; BRAIN; BRAIN CORTEX; BRAIN HOMOGENATE; BRAIN TISSUE; CHEMICAL BINDING; CHIMPANZEE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RHESUS MONKEY; SQUIRREL MONKEY;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANILINE COMPOUNDS; ANIMALS; AUTORADIOGRAPHY; BRAIN; CEREBRAL ANGIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PRIMATES; PROTEIN BINDING; TAU PROTEINS; THIAZOLES; TRITIUM;

EID: 78649846020     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.02.011     Document Type: Article

References (46)

1. Arriagada P.V., Marzloff K., Hyman B.T. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology 1992, 42:1681-1688.
2. Bacskai B.J., Frosch M.P., Freeman S.H., Raymond S.B., Augustinack J.C., Johnson K.A., Irizarry M.C., Klunk W.E., Mathis C.A., DeKosky S.T., Greenberg S.M., Hyman B.T., Growdon J.H. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch. Neurol. 2007, 64:431-434.
3. Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66:1837-1844.
4. Chien P., Weissman J.S., DePace A.H. Emerging principles of conformation-based prion inheritance. Annu. Rev. Biochem. 2004, 73:617-656.
5. Collinge J., Clarke A.R. A general model of prion strains and their pathogenicity. Science 2007, 318:930-936.
6. Crystal H., Dickson D., Fuld P., Masur D., Scott R., Mehler M., Masdeu J., Kawas C., Aronson M., Wolfson L. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988, 38:1682-1687.
7. Cummings J.L. Alzheimer's disease. N. Engl. J. Med. 2004, 351:56-67.
8. Dodart J.C., May P. Overview on rodent models of Alzheimer's disease. Curr. Protoc. Neurosci. 2005, (Chapter 9, Unit 9.22).
9. Elfenbein H.A., Rosen R.F., Stephens S.L., Switzer R.C., Smith Y., Pare J., Mehta P.D., Warzok R., Walker L.C. Cerebral beta-amyloid angiopathy in aged squirrel monkeys. Histol. Histopathol. 2007, 22:155-167.
10. Fodero-Tavoletti M.T., Smith D.P., McLean C.A., Adlard P.A., Barnham K.J., Foster L.E., Leone L., Perez K., Cortes M., Culvenor J.G., Li Q.-X., Laughton K.M., Rowe C.C., Masters C.L., Cappai R., Villemagne V.L. In vitro characterization of Pittsburgh Compound-B binding to Lewy bodies. J. Neurosci. 2007, 27:10365-10371.
11. Giannakopoulos P., Gold G., Kovari E., von Gunten A., Imhof A., Bouras C., Hof P.R. Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathol. (Berl.) 2007, 113:1-12.
12. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
13. Hasegawa K., Yamaguchi I., Omata S., Gejyo F., Naiki H. Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 1999, 38:15514-15521.
14. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., Lopresti B.J., Ziolko S., Bi W., Paljug W.R., Debnath M.L., Hope C.E., Isanski B.A., Hamilton R.L., DeKosky S.T. Post-mortem correlates of in vivo PIB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
15. Johnson K.A., Gregas M., Becker J.A., Kinnecom C., Salat D.H., Moran E.K., Smith E.E., Rosand J., Rentz D.M., Klunk W.E., Mathis C.A., Price J.C., DeKosky S.T., Fischman A.J., Greenberg S.M. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann. Neurol. 2007, 62:229-234.
16. Klunk W.E., Wang Y., Huang G.F., Debnath M.L., Holt D.P., Shao L., Hamilton R.L., Ikonomovic M.D., DeKosky S.T., Mathis C.A. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J. Neurosci. 2003, 23:2086-2092.
17. Klunk W.E., Engler H., Nordberg A., Bacskai B.J., Wang Y., Price J.C., Bergstrom M., Hyman B.T., Langstrom B., Mathis C.A. Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin. N. Am. 2003, 13:781-789. ix.
18. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh Compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25:10598-10606.
19. Klunk W.E., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
20. Kuo Y.-M., Kokjohn T.A., Beach T.G., Sue L.I., Brune D., Lopez J.C., Kalback W.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Roher A.E. Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 2001, 276:12991-12998.
21. Leinonen V., Alafuzoff I., Aalto S., Suotunen T., Savolainen S., Nagren K., Tapiola T., Pirttila T., Rinne J., Jaaskelainen J.E., Soininen H., Rinne J.O. Assessment of {beta}-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch. Neurol. 2008, 65:1304-1309.
22. LeVine H., Walker L.C. Models of Alzheimer's disease. Handbook of Models for Human Aging 2006, 121-134. Academic Press, Burlington. P.M. Conn (Ed.).
23. LeVine H., Walker L.C. Molecular polymorphism of Abeta in Alzheimer's disease. Neurobiol. Aging 2008, 10.1016/j.neurobiolaging.2008.05.026.
24. Lockhart A., Ye L., Judd D.B., Merritt A.T., Lowe P.N., Morgenstern J.L., Hong G., Gee A.D., Brown J. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J. Biol. Chem. 2005, 280:7677-7684.
25. Lockhart A., Lamb J.R., Osredkar T., Sue L.I., Joyce J.N., Ye L., Libri V., Leppert D., Beach T.G. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 2007, 130:2607-2615.
26. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T.C., Suzuki K., Mori H., Higuchi M., Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27:10957-10968.
27. Makarava N., Baskakov I.V. The same primary structure of the prion protein yields two distinct self-propagating states. J. Biol. Chem. 2008, 283:15988-15996.
28. Mathis C.A., Wang Y., Klunk W.E. Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr. Pharm. Des. 2004, 10:1469-1492.
29. McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M.P., Beard J., Das P., Jansen K., Delucia M., Lin W.L., Dolios G., Wang R., Eckman C.B., Dickson D.W., Hutton M., Hardy J., Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005, 47:191-199.
30. Meyer-Luehmann M., Coomaraswamy J., Bolmont T., Kaeser S., Schaefer C., Kilger E., Neuenschwander A., Abramowski D., Frey P., Jaton A.L., Vigouret J.-M., Paganetti P., Walsh D.M., Mathews P.M., Ghiso J., Staufenbiel M., Walker L.C., Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006, 313:1781-1784.
31. 18F]FDDNP. Synapse 2008, 62:472-475.
32. Nordberg A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur. J. Nucl. Med. Mol. Imag. 2008, 35(Suppl. 1):S46-50.
33. Otvos L., Szendrei G.I., Lee V.M.-Y., Mantsch H.H. Human and rodent Alzheimer beta-amyloid peptides acquire distinct conformations in membrane-mimicking solvents. Eur. J. Biochem. 1993, 211:249-257.
34. Petkova A.T., Leapman R.D., Guo Z., Yau W.M., Mattson M.P., Tycko R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science 2005, 307:262-265.
35. Rosen, R.F., LeVine III, H., Pohl, J., Preuss, T.M., Reed, M., Tomidokoro, Y., Farberg, A., Rosene, D.L., Voytko, M.L., Lah, J.J., Murphy, M.P., Gearing, M., Ghiso, J.A., Walker, L.C., 2006. Mass spectrometric detection of modified cerebral Abeta peptides in Alzheimer's disease, aged humans, and aged nonhuman primates. In: 2006 Abstract Viewer/Itinerary Planner. Program No. 170.22. Society for Neuroscience, Washington, DC.
36. Rosen R.F., Farberg A.S., Gearing M., Dooyema J., Long P.M., Anderson D.C., Davis-Turak J., Coppola G., Geschwind D.H., Pare J.F., Duong T.Q., Hopkins W.D., Preuss T.M., Walker L.C. Tauopathy with paired helical filaments in an aged chimpanzee. J. Comp. Neurol. 2008, 509:259-270.
37. 11C]PIB. Bioorg. Med. Chem. Lett. 2009, 19:602-605.
38. Svedberg M.M., Hall H., Hellstrom-Lindahl E., Estrada S., Guan Z., Nordberg A., Langstrom B. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem. Int. 2008, 54:347-357.
39. 11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imag. 2005, 32:593-600.
40. Vinters H.V., Wang Z.Z., Secor D.L. Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol. 1996, 6:179-195.
41. Walker L.C., Cork L.C. The neurobiology of aging in nonhuman primates. Alzheimer Disease 1999, 233-243. Edition Lippincott Williams & Wilkins, Philadelphia. 2nd ed. R.D. Terry, R. Katzman, K.L. Bick, S.S. Sisodia (Eds.).
42. Walker L.C., Pahnke J., Madauss M., Vogelgesang S., Pahnke A., Herbst E.W., Stausske D., Walther R., Kessler C., Warzok R.W. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. Acta Neuropathol. 2000, 100:36-42.
43. Wilcock G.K., Esiri M.M. Plaques, tangles and dementia. A quantitative study. J. Neurol. Sci. 1982, 56:343-356.
44. Ye L., Morgenstern J.L., Lamb J.R., Lockhart A. Characterisation of the binding of amyloid imaging tracers to rodent Abeta fibrils and rodent-human Abeta co-polymers. Biochem. Biophys. Res. Commun. 2006, 347:669-677.
45. Ye L., Morgenstern J.L., Gee A.D., Hong G., Brown J., Lockhart A. Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. J. Biol. Chem. 2005, 280:23599-23604.
46. Ye L., Velasco A., Fraser G., Beach T.G., Sue L., Osredkar T., Libri V., Spillantini M.G., Goedert M., Lockhart A. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J. Neurochem. 2008, 105:1428-1437.